Future Healthcare VB-FIND Innovation Expo: Invitation to Attend and Explore Cutting-Edge Medical Technologies

Dear Exhibitors and Attendees:

In the new era of rapid scientific and technological advancement, medical equipment, as a critical asset and productive resource second only to physicians, plays an increasingly vital role in the service delivery and management of healthcare institutions, and has become an integral component of healthcare quality and safety.

On this basis, the International Exchange and Cooperation Center of the National Health Commission will2023Year8Month11Day-13DayHeld in Beijing, the 29thChina International Medical Equipment Exhibition and Technical Exchange Conference (hereinafter referred to as "2023 China-Hospeq"). To promote multi-party exchanges and cooperation among domestic innovative medical device enterprises, overseas distributors, export enablement service providers, and overseas embassies/institutions stationed in China,National Health Commission International Exchange and Cooperation CenterHand in HandVCBeatVB100, specially curated during the exhibition"Future HealthcareVB-FINDInnovation Exhibition"。

To help attendees better understand exhibitor information and navigate the exhibition, we have compiled an overview of innovative exhibitors’ business profiles. Those interested in their products, services, or business systems are welcome to visit the respective booths for discussions and negotiations.

Innovation ExhibitionOpenIIIDay, all are open for free visits. You are cordially invited to attend in person!

A total of 20 exhibitors participated, as listed below:

*Listed in order of booth number, not by ranking

*Booth Layout Diagram

Tianjin Century Kangtai Biomedical Engineering Co., Ltd.

Booth No.: C26-01

Tianjin Century Kangtai Biomedical Engineering Co., Ltd. (hereinafter referred to as “Century Kangtai”) is a manufacturer of Class III high-end medical devices, integrating research and development, production, and sales. Relying on a high-quality scientific research platform, the company has scientifically formulated a strategic layout of “one main body with two wings, coordinated development,” and has successively been awardedGrant“National High-Tech Enterprise,” “Tianjin ‘Specialized, Refined, Differential, and Innovative’ Enterprise,” “Tianjin Gazelle Enterprise,” and “Tianjin Leading Enterprise in Strategic Emerging Industries.”

Shiji Kangtai has obtained approval for six Class III medical device registrations and filing for two Class II medical device registrations from the National Medical Products Administration (NMPA). In the design of ophthalmic products, its “edge-enhanced zero spherical aberration” and “hollow haptic” features represent domestic innovations in aspheric intraocular lenses. Furthermore, the Class III medical device registration certificate for its collagen sponge is the first full-surgical collagen sponge registration approved by the NMPA under the new standards implemented since 2011.

Shenzhen Guangyu Biotechnology Co., Ltd.

Booth No.:C26-03

Shenzhen Guangyu Biotechnology Co., Ltd. was established inIn 2019, leveraging its core rare-earth fluorescent materials, the company developed a highly cost-effective ultra-sensitive single-molecule detection technology platform, delivering femtogram-level detection solutions for medical research and diagnostics. It pioneered the breakthrough application of rare-earth nanomaterials in in vitro diagnostics (IVD), sparking a new wave of “material revolution.” The core team covers the entire value chain from raw materials to clinical applications and bench-to-bedside translation. The company has obtained NMPA Class III and Class II medical device certifications. It has been selected for national-level projects such as the Key Special Projects of the 14th Five-Year Plan. With parallel advances in scientific research and commercialization, it has achieved significant progress across multiple pipelines, including cancer screening, neurological diseases, and cardiovascular diseases. In the future, the company will expand into more application scenarios based on its core rare-earth technologies, aiming to build a platform enterprise with comprehensive coverage from raw materials to a diversified product pipeline.

Yifang Health Valley

Booth No.:C26-04

Yifang Health Valley is located in the Tongzhou Park of Zhongguancun Science and Technology Park. As the first dedicated pharmaceutical and health industrial park in the Beijing Sub-center, it has been officially included as a key project in the “14th Five-Year Plan for Scientific and Technological Innovation in the Sub-center.” It is eligible to enjoy the benefits under the “Zhongguancun 1policy support such as the “Series 5 Policies,” the “Tongzhou District’s Eight Preferential Policies,” and the “Sub-Center’s Ten Measures to Encourage the Development of the Pharmaceutical and Health Industries.” The park comprises 20 standalone buildings, offering flexible spaces ranging from 200 to 5,000 square meters to meet office and R&D needs.Fa, GMP laboratories, small-scale and pilot-scale trials, assembly production, medical institutions, and other operational scenarios. The park has established five major service platforms covering policy, finance, entrepreneurial incubation, resource sharing, and talent development, and has created the first professional healthcare incubator in the Sub-Center based on the Tongzhou District makerspace, providing comprehensive services to support enterprise growth.

Zhonghui Medical Imaging Co., Ltd.

Booth No.: C26-05

Zhonghui Medical Imaging was established inIn 2012, it was a global leader in providing 3D ultrasound imaging technologies, equipment, and solutions.

CourseWith 20 years of technological accumulation and 10 years of clinical exploration, the Scolioscan® 3D ultrasound imaging platform features 19 globally pioneering and leading technologies. It provides monitoring and assessment for early diagnosis of chronic diseases, spinal deformities, bone deformities, and other conditions. By offering a radiation-free solution, it helps specialties such as orthopedics, rehabilitation, and sports medicine achieve more precise, standardized, and visualized diagnosis and treatment.

Scolioscan®It is the world’s first and only ultrasound-based scoliosis assessment system, boasting a patent cluster of more than 26 patents and a total of over 100 patents, and has won numerous major awards in various international innovation competitions. Scolioscan® has completed clinical trials and medical device certification in Europe, Australia, and China, and is widely used in hospitals and clinics.

Jingzhi Future (Guangzhou) Intelligent Technology Co., Ltd.

Booth No.: C26-06

Jingzhi Future (Guangzhou) Intelligent Technology Co., Ltd. (ChromX Health is a high-tech enterprise with leading technologies and products in the global field of breath diagnostics, dedicated to comprehensively decoding metabolic molecular information in human exhaled breath through revolutionary innovative technology. The company creatively integrates Micro-Electro-Mechanical Systems (MEMS), microfluidics, and artificial intelligence (AI) technologies. Grounded in the theory of breath metabolomics, it has independently developed and manufactured the world’s first ultra-sensitive, high-resolution, intelligent, point-of-care testing (POCT) breath molecular analysis chromatograph, enabling precise qualitative and quantitative analysis of volatile organic compounds (VOCs) in respiratory gases.

Chengdu Yilexin Biotechnology Co., Ltd.

Booth No.: C26-08

Chengdu Yilexin Biotechnology Co., Ltd., established on August 30, 2018, is a National High-Tech Enterprise and a Sichuan Province Technology-Based Small and Medium-sized Enterprise. The company specializes in the research, development, and manufacturing of single-test chemiluminescence assays, single-test flow fluorescence assays, and laboratory automation products, while providing the industry with open ecosystem platforms and comprehensive solutions for chemiluminescence and flow fluorescence technologies.

The company has accumulated extensive technical expertise in chemiluminescence, flow fluorescence, coded microspheres, supporting diagnostic reagents, core components, and single-test reagent production equipment, while mastering multiple proprietary technologies. Its “5A-grade” diagnostic system has set a new industry benchmark, with products covering Europe, the Middle East, South Asia, South America, Africa, and major provinces, municipalities, and autonomous regions across China, earning consistent acclaim from customers both domestically and internationally.

Yilexin will continue to focus on clinical value and needs, providing accessible, comprehensive precision diagnostics solutions for global partners, and strive to become a value innovator in the global IVD industry!

Xiamen Jiyuan Medical Technology Co., Ltd.

Booth Number: C26-09

Xiamen Jiyuan Medical Technology Co., Ltd. (hereinafter referred to as "Genokon") is a national high-tech enterprise specializing in early screening for pediatric genetic disorders, clinical gene-assisted diagnosis, and digital diagnostic and therapeutic services. As a member unit of the Chinese Alliance for Rare Diseases (the sole corporate member from Fujian Province), Genokon is committed to the deep integration of information technology (IT), biotechnology (BT), and medical technology (MT). The company provides comprehensive empowerment for the clinical application of genetic diagnosis of hereditary diseases, establishing a new paradigm of precision medicine driven by "data + algorithms + computing power." To date, the company’s digital platform has been deployed and utilized in dozens of leading hospitals across China, including the Chinese Center for Disease Control and Prevention, West China Hospital, Xinhua Hospital, Beijing Children’s Hospital, Ruijin Hospital, Fudan University Obstetrics & Gynecology Hospital, and the Chinese PLA General Hospital.

Yishan Medical Technology Co., Ltd.

Booth No.: C26-10

Yishan Medical, founded in 2019 at the National University of Singapore, is committed to creating full-cycle maternal and child healthcare products and services covering pregnancy, childbirth, and childcare, providing globally leading digital home health solutions.

As an R&D-driven pioneer in POCT medical device innovation, the company’s core team has dedicated many years to the fields of optoelectronics and information technology. Hailing from world-class institutions such as the National University of Singapore, Johns Hopkins University, the University of California, Berkeley, and Tsinghua University, the team has secured over 60 domestic and international patents and technological achievements. To date, Yishan has completed multiple rounds of financing, with investors including the National University of Singapore, Hong Kong X Fund, South Korea’s SUNBO Angel Fund, and Singapore Industrial Fund; it has also received support from government funds in Singapore and Hong Kong. Headquartered at Science Park Singapore, the company has established its R&D teams in Shenzhen Qianhai and Hong Kong Science Park, while operating a self-built manufacturing facility in the Pingshan Industrial Zone of Shenzhen.

The company has obtained ISO 13485 certification for its medical device quality management system. Products such as the intelligent neonatal jaundice meter have received medical device registration certificates from China’s National Medical Products Administration (NMPA, formerly CFDA) and clearance from the U.S. Food and Drug Administration (FDA). Currently, the Yishan YSJ-20 intelligent neonatal jaundice meter has been adopted by more than 100 maternal and child health hospitals and Grade A tertiary hospitals in China, and entered the African and Southeast Asian markets in 2023.

Xiamen Area of the Fujian Pilot Free Trade ZoneManteia Data Technology Co., Ltd.

Booth Number: C26-11

Xiamen Area of the Fujian Pilot Free Trade ZoneManteia Data Technology Co., Ltd. (“Manteia”), founded in 2017, is a company specializing in the research and development of medical software in the field of Adaptive Radiation Therapy (ART), leveraging deep learning and traditional medical algorithms. The company focuses on the R&D of radiation therapy-related products, including product lines such as “Radiation Therapy Contouring Software,” “Deep Learning Autonomous Training Platform,” “Information and Data Systems,” “Quality Control Analysis System,” “Cloud Radiotherapy and Remote Radiotherapy Systems,” and “ART Adaptive Radiotherapy.” It is committed to making tumor radiation therapy safer, more precise, and more efficient, thereby fundamentally achieving precision radiotherapy. In 2020, the company’s products successively obtained FDA, CE, and NMPA Class III marketing approvals. They have entered markets in China, the United States, Canada, South Korea, Europe, Southeast Asia, and other regions, serving over 1,000 hospitals domestically and internationally, with a leading market share among similar products.

MedRhein GmbH

Booth Number:C26-12

Mei de Yin(MedRhein) focuses on the German-speaking region, serving as a full-process service provider that empowers medical device companies to expand into this market through digitalization. MedRhein’s parent company, CTG, was established in 1993 and is an expert in cross-border exports of medical products between China and Europe. Leveraging CTG’s decades of profound experience in the German-speaking region and MedRhein’s own strengths, the company has rapidly established a complete pathway for Chinese IVD enterprises to enter the German-speaking market. By utilizing data analysis to efficiently identify market demands in the German-speaking region, the company assists domestic enterprises with product compliance, warehousing and logistics transportation, localized product packaging, and market sales. To date, it has partnered with over 50 Chinese IVD companies. As a bridge connecting the German-speaking region and China, MedRhein remains committed to removing obstacles for Chinese enterprises expanding into the German-speaking region, facilitating their entry into the German-speaking and EU markets, and enhancing the international influence of Chinese IVD companies.

Shanghai Wanmaid Medical Consulting Service Co., Ltd.

Booth No.: C26-13

Ji Kang Wan Jia is the cross-border medical service brand under Medical Note, Japan’s largest online healthcare service platform. With bases in Tokyo, Japan, and Shanghai (Shanghai Wanmaidie Medical Consulting Service Co., Ltd.), Ji Kang Wan Jia adheres to the philosophy of “connecting doctors and patients.” It provides overseas patients, primarily from China, with remote consultations, medical treatment in Japan, chronic disease management, health check-ups in Japan, and other personalized medical services.

Leveraging the robust medical background of the Medical Note Group, Xikang Wanjia has, to date, established friendly cooperative relationships with 1,100 medical institutions—including the National Cancer Center, the National Center for Global Health and Medicine, Tokyo Medical University Hospital, and Juntendo Hospital—as well as over 2,700 medical experts, serving as a vital bridge connecting Chinese patients to Japan’s top-tier medical resources.

Beijing Weimai Medical Equipment Co., Ltd.

Booth No.: C26-14

Beijing Weimai Medical Equipment Co., Ltd. shoulders the responsibility of fostering the rise of high-end national medical brands and has been recognized as a specialized, refined, distinctive, and innovative “Little Giant” enterprise by the Ministry of Industry and Information Technology of China. Weimai Medical is professionally dedicated to providing interventional diagnosis and treatment equipment along with comprehensive end-to-end solutions, boasting many years of experience in the research, design, and industrialization of digital vascular imaging products, with its product portfolio coveringLarge Angiography System(DSA), MobileXRadiationCC-arm, MobileXRayCC-arm All-in-One System, Interventional Robotand other interventional product lines.

The company has partnered with an interventional physician group to introduce the distinctive “comprehensive service” concept, actively expanding into interventional fields such as departmental operations and physician training. It has achieved ISO 13485 certification, while its full range of interventional products has obtained both CE and NMPA certifications. Committed to innovation-driven development, the company is a global leader in the research and development of interventional surgical robots, ranking among only five companies worldwide engaged in their production and R&D. Furthermore, it holds the second-highest number of pioneering invention patents in the international robotics sector.

In close alignment with China’s national “Belt and Road” strategic policy, we completed the acquisition of Italy’s EUROCOLUMBUS company, established a dual global center framework, and achieved an international strategic layout encompassing product R&D, manufacturing, and market sales.

Shenzhen Huiliuti Biotechnology Co., Ltd.

Booth Number: C26-15

Shenzhen Huiliu Biotechnology Co., Ltd. is aAn R&D and manufacturing enterprise for AI-powered in vitro diagnostics (IVD) platforms, specializing in providing integrated "hardware + software + service" solutions to primary healthcare institutions. Its Cube series, a laboratory automation solution tailored for small and medium-sized medical institutions, is the world’s first compact intelligent testing assembly line. By integrating in vitro diagnostics, robotics design, and artificial intelligence technologies, it enables a fully functional medical testing laboratory within just 1 square meter, significantly enhancing diagnostic capabilities and operational efficiency for smaller healthcare providers. The next-generation intelligent Point-of-Care Testing (POCT) analysis system, the Mini Cube series, innovatively employs microfluidics and flow cytometry technologies to integrate complete blood count, biochemical, and immunoassay analyses. It allows multi-platform testing from a single blood sample using one instrument with a single-step operation, empowering primary care testing services through cost-effectiveness and highly integrated design. Currently, the company has established R&D centers in Shenzhen and Silicon Valley, dedicated to advancing the development of the digital healthcare industry.。

Ximu High-Tech (Jiangsu) Co., Ltd.

Booth No.: C26-16

Xim Medical is committed to providing innovative and intelligent surgical equipment for medical institutions, transforming surgical practices through cutting-edge medical devices to benefit patients. In 2019, the company launched the world’s first digital flat-panel C-arm, which was highly acclaimed upon its market release. Currently, Xim Medical’s products are being used by over 100 hospitals, including the Chinese PLA General Hospital, Peking University Third Hospital, the Third Hospital of Hebei Medical University, Xijing Hospital, and Xinqiao Hospital. Moving forward, Xim Medical will continue to prioritize innovation, delivering imaging equipment that supports precision, minimally invasive procedures, convenience, intelligence, collaboration, and reusability, enabling more patients to benefit from the power of innovation.

iBu (Shanghai) Artificial Intelligence Technology Co., Ltd.

Booth Number: C26-17

EXOATLETThe group was established in 2014 and is dedicated to the research, development, and manufacturing of exoskeleton robots. It is a multinational technology corporation leading the global exoskeleton sector.

ExoatletChina (Aibu AI) was established in 2019 as a wholly-owned subsidiary incubated by the ExoAtlet Group in China. In 2022, it founded an intelligent robotics manufacturing base in Shanghai, seamlessly integrating artificial intelligence with robotics to provide intelligent robot and exoskeleton solutions for the healthcare and industrial sectors, as well as for society’s aging population.

Shanghai Tongshu Biotechnology Co., Ltd.

Booth Number:C26-20

Tongshu Gene is a high-tech enterprise centered on technological innovation and dedicated to precision molecular diagnostics for oncology. Headquartered at the Chenggong Technology Oasis in Baoshan, Shanghai, the company has established facilities in Shanghai and Changzhou that comply withA GMP-compliant production center and an international-standard medical laboratory testing center.

Tongshu Gene has always adhered to the mission of “Innovation • Creating Value for Cancer Patients,” integrating R&D, production, and sales of molecular diagnostics for oncology. Leveraging its “multi-platform layout” strategy, itGenetic testing services leveraging NGS-based ultra-low input library preparation as a core technological barrier, together with a big-data translational research center built upon a tumor genomics biobank, have established competitive advantages. The company’s independently developed microsatellite instability (MSI) detection kit received China’s first Class III medical device registration certificate for MSI testing in January 2021, filling a gap in the field of precision diagnosis and treatment in China and benefiting three million cancer patients nationwide.

Kuante (Beijing) Medical Device Co., Ltd.

Booth No.: C26-21

Kuanteng (Beijing) Medical Devices Co., Ltd., headquartered in Beijing, is a leading domestic supplier of medical equipment. The company has established branches in Shanghai, Shenyang, Hangzhou, Anhui, and other regions. Its core business encompasses self-developed imaging equipment for human medicine, including CT, DR, MR, and mini C-arms.The company boasts leading R&D capabilities and technological prowess within China. It possesses the most robust radiology R&D team in the country, with substantial investment in research and development; the R&D intensity ratio reaches as high as 15%, ranking first in China for R&D efficiency. In 2021, its CT business achieved comprehensive growth. Photon-counting detector CT technology is paving the way for the future, while MR systems feature fully independent R&D, technological upgrades, and innovation. The company’s product portfolio covers the entire market spectrum for both superconducting and permanent magnet MR systems.To better align with regional user needs, the company plans to establish a nationwide footprint by building independent R&D and manufacturing bases for imaging products in Northern, Eastern, and Southern China. Currently, the company has established four production bases (Benxi, Hangzhou, Anhui, and Fujian) and three R&D centers (Beijing, Shenyang, and Hangzhou) across the country.Self-Developed Human Medical Imaging Business: Full Industry Layout: The company has established a comprehensive presence across the CT, DR, MRI, and mobile C-arm sectors, with all products independently researched, developed, and manufactured. Currently, only four companies in China have achieved such a layout. The company offers over 20 DR models, 10 CT models, and 7 MRI models, comprehensively covering markets ranging from high-end tertiary hospitals to grassroots community health centers. The company’s DR shipment volume ranks among the top three enterprises in China. Furthermore, its leadership in DR products will significantly drive market sales of its CT and MRI offerings. Core components for CT, MRI, and DR systems are all independently developed and manufactured. Notably, the CT photon-counting detector project has been selected as a national “Bai Cai Xin” (core technology) project. Key MRI components, including spectrometer systems, gradient systems, and high-order shimming coils, are all self-developed. This not only greatly enhances product stability and overall performance but also ensures that the company’s product costs are significantly lower than those of domestic competitors, providing strong market competitiveness. High-End Product Layout for Tertiary Hospitals: The company has established a production base for high-end imaging products in Hangzhou, focusing on the research, development, and manufacturing of premium equipment such as 62-slice/124-layer, 64-slice/128-layer, and 128-slice/256-layer CT scanners, large-bore 64-slice CT scanners, 1.5T integrated-coil MRI systems, and 3.0T MRI systems, thereby concentrating on expanding into the high-end market of tertiary hospitals.

Simede (Jiaxing) Medical Technology Co., Ltd.

Booth Number:C26-22

Simed Medical Technology Group is committed to the mission of leveraging innovative technologies and premium services to deliver value that exceeds customer expectations. It is dedicated to providing comprehensive technical solutions to clients in the healthcare industry, enabling medical device companies to focus on serving clinical needs.

Technical fields involved: optoelectronic technology, precision machinery, software development, circuit design, precision machining, mold manufacturing, injection molding, intelligent manufacturing of production lines, medical device registration, regulatory training for the healthcare industry, and consulting services.

Fusote (Shanghai) Medical Technology Co., Ltd.

Booth No.:C26-23

Fusote (Shanghai) Medical Technology Co., Ltd. is a high-tech company long dedicated to the research and development, manufacturing, sales, and service of intelligent, portable, and innovative medical devices.

The company boasts a scientific R&D team of dozens, comprising medical research experts, clinical medicine specialists, Ph.D. holders in electrical engineering, computer science Ph.D. researchers specializing in algorithms, and experts in the field of medical rehabilitation, demonstrating robust capabilities in the research and development of cutting-edge technologies for medical devices.

Fusote Medical has long been dedicated to developing intelligent, portable, and cutting-edge medical technologies. By breakthroughly applying innovative smart optical sensing technology, precise terrain scanning technology, multi-sensor information fusion technology, and leading digital twin technology, it has independently developed ““Forethought Fusote – Spinal Data Acquisition and Analysis System” and “Xiaoshu Classmate – Spinal Detector” have made spinal assessment simple and lightweight for the first time! This product series has been granted multiple national invention patents and has passed the novelty search conducted by the Chinese Academy of Sciences.。

Beijing Daxing International Airport Comprehensive Bonded Zone Biopharmaceutical Incubator

Booth Number:C26-24

Beijing Daxing International Airport Comprehensive Bonded Zone Biopharmaceutical Incubator (DB-PARK) is the inaugural project for the nation’s top-priority initiative and leading industry, bringing together world-class CROs, CDMOs, emerging technology and testing service providers, as well as high-end consumables manufacturers and traders. It aims to become a biomedical R&D and manufacturing services hub serving Beijing, China, and the global market.

Planned Construction Area of the Project: Approximately130,000 square meters, with R&D in the front and production in the back, and independent functions. Among them, the first phase of 70,000 square meters has been completed and is about to be put into use, carrying the functions of bonded R&D and bonded production base.

DB-PARKAs a premier brand in the biomedical sector of the Daxing Airport Economic Zone, and as a highland connecting China with global sources of innovation, DB-PARK will join hands with Beijing Daxing International Airport to link up with the world.

2023Summit on Medical Device Product Innovation and International Cooperation

Time: August 12, 9:00–16:00

Venue: China National Convention Center · Lecture Hall

ByVCBeatVB100Hosted by,National Health Commission International Exchange and Cooperation CenterAs a supporting organization, it will8Month12DayInLecture Hallheld. The conference focuses on the import and export trade of medical devices, with “Global Innovation and International Cooperation” as its core theme. Adopting a global perspective, it will conduct in-depth discussions on topics such as innovation and upgrading of medical devices, brand globalization, cross-border trade, international strategic layout, and team building and management, thereby fostering collaboration among domestic innovative medical device enterprises, overseas distributors, providers of global expansion enablement services, and foreign embassies in China/Multi-party Exchange and Collaboration among Institutional Platforms. Focusing on the current state and challenges of the industry, this initiative analyzes the status of medical device exports, shares corporate experiences in technological innovation, business model innovation, brand building, overseas operations, and investment and financing trends, while exploring trade trends, innovative applications, and industrial cooperation within the context of global policies, economics, and markets.

*Note: The agenda is for reference only and subject to final on-site confirmation.

Note: Welcome to click the “China-Hospeq” digital exhibition hall to connect with more high-quality exhibitors:http://digital.chinahospeq.com/cn/#/